Clinical Trial Results:
Ranibizumab in idiopathic macular telangiectasia, type2
A prospective interventional non-randomized study comparing the efficacy and safety of intravitreal ranibizumab (dosing regimen 0.5mg every month over a period of one year) in type 2 idiopathic macular telangiectasia
[Intravitreales Ranibizumab zur Therapie von idiopathischen makulären Teleangiektasien, Typ 2]
Summary
|
|
EudraCT number |
2006-006233-40 |
Trial protocol |
DE |
Global completion date |
10 Jul 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
19 Feb 2022
|
First version publication date |
19 Feb 2022
|
Other versions |
|
Summary report(s) |
Ranibizumab in MacTel |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.